Assembly Biosciences (NASDAQ:ASMB)

CAPS Rating: 1 out of 5

Caps

How do you think ASMB will perform against the market?

Add Stock to CAPS Watchlist

All Players

29 Outperform
11 Underperform
 

All-Star Players

5 Outperform
8 Underperform
 

Wall Street

3 Outperform
0 Underperform
 

Top ASMB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

corkbouy (54.15)
Submitted July 21, 2011

The clearance will soon come from the fed. for this the first drug of its kind. Now Dr.s can prescribe a med for this type of problem.

drugtrader (88.91)
Submitted March 04, 2015

Temporary red thumb. Likely resistance above this price. However, the receptor described in the score leader taunt is actually a useful pathway for treating inflammation and may prove positive in trials.The company was previously known as Ventrus… More

ASMB VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ASMB.

Recs

0
Member Avatar rhallbick (95.59) Submitted: 5/9/2018 6:48:40 AM : Outperform Start Price: $54.47 ASMB Score: -56.17

Assembly Biosciences, Inc. (NASDAQ Capital Market: ASMB)
.
Thesis: Speculative CAPS-only pick, not a recommendation. Company prospects are down somewhat since pick was made.
_____________________________________________________________________________________
.
Assembly Biosciences (ASMB) was created in mid-2014 when publicly-traded dollar-stock, Ventrus Biosciences Inc. (NASDAQ: VTUS), acquired privately-owned Assembly Pharmaceuticals, Inc. in an all-stock deal. On the same day, the merged company effected a 1-for-5 reverse stock split, raising its shares out of the penny-stock realm. The company also changed its name to Assembly Biosciences, and began trading on NASDAQ under the symbol ASMB.

ASMB has legacy developmental products from Ventrus, who had focused on developing and commercializing drugs for gastrointestinal disorders; specifically hemorrhoids, anal fissures, and fecal incontinence. They have a collaboration agreement with Allergan Pharmaceuticals Int'l Ltd. for the development and commercialization of selected microbiome gastrointestinal programs.

The former Assembly Pharmaceuticals was developing a new class of oral small-molecule therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. Specifically, they were, and are, involved in the development of core protein allosteric modulators (CpAM) that modulate the HBV core protein at various points in the viral lifecycle.

ASMB has released interim data on a Phase 1b/2a study of their novel CpAM candidate ABI-H0731 for the treatment of chronic HBV infection. The data is encouraging, as the drug is seen as effective, generally safe and well tolerated, and no dose limiting side effects were seen.

Competitors of ASMB with similar-acting drugs have also been releasing their own Phase II study data with similar results, so ASMB does not stand out as having the superior drug at this time. Johnson & Johnson is developing JNJ-56136379, Hoffmann-La Roche is developing RO7049389, and Spring Bank Pharmaceuticals is developing inarigivir soproxil (formerly known as SB 9200).

There are currently effective treatments in the marketplace for HBV, but not yet a functional cure. The goal is to find a drug combination that will permanently cure HBV infected patients. Combination therapies in Phase II studies may provide for an aseptic cure, but it is not clear now which company or companies will be successful. Many years of drug development still lay ahead of them.

Stock is covered by at least six analysts with a $45-$84 price target range (average $58.00). Higher estimates may be from before the Apr 12th EASL’s 2018 International Liver Congress, where ASMB, Johnson & Johnson and Hoffmann-La Roche all presented some of their Phase II data for their similar drugs, and ASMB was found not to have any significant advantages over their competitors, and to be slightly behind in the progress of their trials.

As of May 2, 2018, there were 20,550,718 common stock shares outstanding.
Short interest reported on Apr 13, 2018 was 502,904 shares, which is 2.4% of total shares.

Price: $54.47 | Annual Dividend: $0.00 | Dividend Yield: 0.00%

Recs

0
Member Avatar ptanabe (< 20) Submitted: 8/5/2013 2:23:20 PM : Outperform Start Price: $12.77 ASMB Score: +19.06

k

Recs

0
Member Avatar carefulguy (< 20) Submitted: 11/16/2011 1:37:23 AM : Outperform Start Price: $40.75 ASMB Score: -154.90

Currently undervalued based on large market potential of a Hemorrhoids treatment (first to market - currently no treatment available). Good cash balance, and upcoming Q2 2012 PIII pivotal clinical trial results of two drugs. Currently trading at very low volume, once interest picks up, pps will go up.

Leaderboard

Find the members with the highest scoring picks in ASMB.

Score Leader

loangolfer

loangolfer (< 20) Score: +278.34

The Score Leader is the player with the highest score across all their picks in ASMB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
loangolfer < 20 5/5/2014 Outperform 5Y $5.25 +317.52% +39.18% +278.34 0 Comment
peregrine 98.50 4/7/2014 Outperform 5Y $5.85 +274.70% +41.39% +233.31 0 Comment
williamstep 98.76 5/23/2011 Underperform 5Y $87.80 -75.03% +97.49% +172.52 0 Comment
EclecticRecluse 78.82 5/16/2011 Underperform 3W $97.35 -77.48% +95.02% +172.50 1 Comment
Zergum < 20 2/18/2014 Outperform 5Y $8.00 +174.00% +41.41% +132.59 0 Comment
anchak 99.90 2/13/2014 Outperform NS $8.00 +174.00% +42.80% +131.20 0 Comment
ababrmon 71.14 2/12/2014 Outperform 1Y $8.50 +157.90% +42.70% +115.20 0 Comment
Biotechbillions < 20 7/16/2013 Outperform 5Y $11.05 +98.37% +54.80% +43.57 0 Comment
WildShaman 91.88 7/5/2018 Underperform 5Y $39.67 -44.74% -4.30% +40.45 0 Comment
Momentum21 95.66 10/4/2017 Underperform 5Y $35.00 -37.36% +2.97% +40.34 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCantorFitz 39.80 4/5/2012 Outperform NS $54.80 -60.00% +86.88% -146.88 0 Comment
TrackWMBlair 77.39 4/4/2012 Outperform NS $50.98 -57.00% +86.13% -143.13 0 Comment
TrackRodmanRen < 20 2/2/2011 Outperform NS $32.45 -32.45% +99.75% -132.20 0 Comment

Advertisement